A research-based biotechnology company based in Madison, Wisconsin

Administration – Madison, WI

Production – Middleton, WI

At Quincy Bioscience, we are committed to improving the quality of life, with a special focus on aging, for people worldwide. Through a truly unique platform technology, Quincy Bioscience researches, develops and plans to market therapeutic compounds for the treatment of the most prevalent neurodegenerative disorders, such as Alzheimer’s disease and Parkinson’s disease as well as less common but incredibly debilitating conditions like ALS (also known as Lou Gehrig’s disease). On the surface these diseases appear unrelated but at their core a common feature emerges, the neuron’s inability to manage intracellular calcium creating the catalyst for cell death.

The platform technology for future therapeutics is the jellyfish derived calcium-binding protein apoaequorin. In all mammals calcium-binding proteins are important in the protection of cellular populations against toxic calcium overload, especially nerve cells, and decrease in number over the course of aging or disease progression.

Early in 2010, the company was issued its first patent for the use of apoaequorin in a therapeutic manner. Research and development work is conducted in university laboratories and Quincy Bioscience’s own facilities.